- Home
- GNLX vs ZNTL Comparison
GNLX vs ZNTL Comparison
Compare GNLX & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNLX
- ZNTL
- Stock Information
- Founded
- GNLX 2001
- ZNTL 2014
- Country
- GNLX United States
- ZNTL United States
- Employees
- GNLX N/A
- ZNTL N/A
- Industry
- GNLX Biotechnology: Pharmaceutical Preparations
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- GNLX Health Care
- ZNTL Health Care
- Exchange
- GNLX Nasdaq
- ZNTL Nasdaq
- Market Cap
- GNLX 128.0M
- ZNTL 105.8M
- IPO Year
- GNLX 2023
- ZNTL 2020
- Fundamental
- Price
- GNLX $3.95
- ZNTL $1.49
- Analyst Decision
- GNLX Strong Buy
- ZNTL Buy
- Analyst Count
- GNLX 4
- ZNTL 7
- Target Price
- GNLX $17.75
- ZNTL $8.46
- AVG Volume (30 Days)
- GNLX 134.7K
- ZNTL 830.4K
- Earning Date
- GNLX 11-13-2025
- ZNTL 11-11-2025
- Dividend Yield
- GNLX N/A
- ZNTL N/A
- EPS Growth
- GNLX N/A
- ZNTL N/A
- EPS
- GNLX N/A
- ZNTL N/A
- Revenue
- GNLX N/A
- ZNTL $26,865,000.00
- Revenue This Year
- GNLX N/A
- ZNTL N/A
- Revenue Next Year
- GNLX N/A
- ZNTL N/A
- P/E Ratio
- GNLX N/A
- ZNTL N/A
- Revenue Growth
- GNLX N/A
- ZNTL N/A
- 52 Week Low
- GNLX $1.95
- ZNTL $1.01
- 52 Week High
- GNLX $5.89
- ZNTL $5.44
- Technical
- Relative Strength Index (RSI)
- GNLX 63.93
- ZNTL 43.18
- Support Level
- GNLX $3.56
- ZNTL $1.60
- Resistance Level
- GNLX $3.61
- ZNTL $2.02
- Average True Range (ATR)
- GNLX 0.24
- ZNTL 0.13
- MACD
- GNLX 0.03
- ZNTL -0.04
- Stochastic Oscillator
- GNLX 84.42
- ZNTL 5.36
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.